Infarction

Subscribe to Selected New Research on Infarction

9732 relevant articles (489 outcomes, 1005 trials/studies) found for this Disease

Description: Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS.

Also Known As:

Infarctions

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2442

Related Diseases

1.	Myocardial Infarction
2.	Ischemia
3.	Heart Failure
4.	Stroke (Strokes)
5.	Brain Ischemia (Cerebral Ischemia)

Experts

1.	Boyko, Valentina: 6 articles (08/2006 - 04/2002)
2.	Goldbourt, Uri: 6 articles (08/2006 - 04/2002)
3.	Behar, Solomon: 6 articles (08/2006 - 04/2002)
4.	Haim, Moti: 4 articles (08/2006 - 04/2002)
5.	Tanne, David: 4 articles (08/2006 - 04/2002)
6.	Uchihara, Toshiki: 3 articles (09/2007 - 08/2003)
7.	Nakamura, Ayako: 3 articles (09/2007 - 08/2003)
8.	Higgins, Charles B: 3 articles (11/2006 - 09/2002)
9.	Saeed, Maythem: 3 articles (11/2006 - 09/2002)
10.	Downey, James M: 3 articles (07/2006 - 12/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Infarction:

1.	glucuronyl glucosamine glycan sulfate (Vessel)IBA 02/01/1999 - "Furthermore, no MRI findings were distinct predictors of long-term prognosis, although infarction based on the small vessel disease had rather good outcome in terms of respiratory disease." 09/01/1997 - "The impact of these changes on infarct healing and their association with the improved prognosis of a patent infarct vessel following infarction will require further study." 01/01/2005 - "Baseline characteristics were similar in both groups with a mean lesion length of 34.89+/-11.19 mm, and vessel diameter of 3.03+/-0.54 mm. CBA resulted in reduced incidence of side branch loss (23.2% versus 41.7%, P=0.022) which was associated with less peri-procedural infarction (OR: 11.39 (95% CI: 1.34-96.53), P=0.026). " 12/01/2007 - "The goal of this study was to determine the frequency of subcortical and deep lacunar lesions and its association with large vessel atherosclerotic infarction at the Ali-Ibne-Abi Taleb Hospital, Rafsanjan. " 07/01/2002 - "Neuropathological study of brain and brain vessels was performed in two series of 12 and 20 centenarians, focusing on the prevalence of small vessel lesions, infarction, Alzheimer's changes and mental status. " Order ALL the reference details at left...
2.	Heparin (Liquaemin)FDA LinkGeneric 02/01/1995 - "Completed clinical trials lead to the following conclusions: 1. The efficacy of heparin in the acute phase of CVA is unknown, given the many biases and methodological imprecisions contained in the studies performed so far, among them a reliance on temporal rather than etiological classification of infarctions and the small number of patients treated. " 01/01/1988 - "These observations suggest that additional controlled studies of the efficacy of heparin in progressing ischemic infarction are warranted." 03/01/1977 - "Enhancement of the enzymic activity in patients, for instance by heparin, may be helpful in mesenteric infarction disease." 06/01/2006 - "We found that the size of an acute infarction calculated on DWI is the risk factor of symptomatic ICH during intravenous heparin therapy in patients with posterior circulation infarct. " 11/01/2005 - "CONCLUSION: After adjustment for baseline differences and propensity to undergo early PCI, DTIs appeared to be more effective than heparin in reducing death or re-infarction among patients undergoing early PCI." Order ALL the reference details at left...
3.	Nitroglycerin (Dynamite)FDA LinkGeneric 06/27/1983 - "Preliminary studies in patients with acute infarction have confirmed the beneficial effect of intravenous nitroglycerin on S-T segment elevation, and a subsequent study in 31 patients with acute infarction showed a decrease in infarct size with improved hemodynamics. " 12/16/1993 - "Two subsequent clinical studies in the thrombolytic era, with low-dose intravenous nitroglycerin infusion during infarction over the first 48 hours followed by buccal nitrate (eccentric dose regimen) or placebo during healing over 6 weeks postinfarction, indicated that prolonged nitrate therapy effectively limited left ventricular remodeling and improved function further compared with placebo." 04/01/1988 - "Thus, reduced expansion and thinning with nitroglycerin during the first week after infarction improved function, mechanical strength, and resistance to distension at 6 weeks." 05/01/1982 - "Early after infarction, sublingual nitroglycerin improved left, right and regional ejection fraction at the infarct site in some patients. " 04/01/1981 - "Within 24 hours, central chord shortening in the zone of infarction was reduced to 13.1 +/- 9.8%, but improved 27.2 +/- 18.4% (p less than 0.001) after nitroglycerin. " Order ALL the reference details at left...
4.	Verapamil (Calan)FDA LinkGeneric 06/01/1992 - "The findings of the DAVIT II study with verapamil demonstrate a significant reduction in the infarction recurrence rate (18% vs 21.6%) in the treatment group. " 12/01/1990 - "reinfarction or death, has been investigated in two Danish double-blind, placebo-controlled verapamil infarction trials DAVIT I and II. DAVIT I, which was an early intervention trial, demonstrated that after six months there was a statistically non-significant reduction of mortality and reinfarction. " 01/01/1993 - "In the Danish Verapamil Infarction Trial II (DAVIT II), treatment with verapamil 360 mg/day improved reinfarction-free survival compared with administration of placebo. " 05/01/1999 - "Danish Verapamil Infarction Trial." 04/15/1999 - "Danish Verapamil Infarction Trial." Order ALL the reference details at left...
5.	Streptokinase FDA Link 06/01/1986 - "Comparison of radionuclide left ventricular ejection fraction assessed acutely (28 +/- 10 hours after infarction) with left ventricular ejection fraction at hospital discharge (15 +/- 3 days after infarction) showed no significant improvement in either the streptokinase or control group, 0% and +1%, respectively. " 02/01/1992 - "The streptokinase-induced reduction in blood viscosity may lead to an improvement in microcirculation in the infarction area during the early phase, whereas the hyperviscosity observed independently of therapy after 1 week may lead to an impairment of microcirculation." 03/01/2000 - "METHODS: Two hundred fifty-eight AMI patients from the Thrombolytics and Myocardia Infarction phase 7 and Global Utilization of Streptokinase tPA for Occluded coronary arteries phase 1 trials were stratified based on blinded, simultaneous reperfusion assessment on the acute angiogram (divided into TIMI grades 0 & 1, TIMI grade 2 and TIMI grade 3) and ST-segment resolution analysis (divided into: <50% ST-segment elevation resolution or reelevation and > or =50% ST-segment elevation resolution). " 09/01/1996 - "METHODS: We studied 24 patients in the Australian Streptokinase Trial with acute middle cerebral cortical infarction using 99mTc-hexamethylpropyleneamine oxime single-photon emission CT. " 03/01/1996 - "Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial." Order ALL the reference details at left...
6.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/20/2005 - "These results suggest that aspirin should not be routinely used in CHF patients and be avoided in those with refractory CHF, but that it may be beneficial in patients with recent infarction or multiple vascular risk factors." 05/01/1994 - "Aspirin is effective in preventing morning infarction. " 08/01/1995 - "The ISIS studies demonstrated the advantages of combining beta-blockers, thrombolysis and aspirin in acute infarction. " 05/01/1995 - "The prevention of heart infarction with 100 mg aspirin is common practice in Germany, in spite of the fact that it is based on only two small studies, the results of which are not generalized. " 08/01/1994 - "We studied the occurrence of silent infarction in a sample of patients from the Dutch TIA trial, in which patients were randomized between 30 and 283 mg of aspirin. " Order ALL the reference details at left...
7.	Diltiazem (Cardizem)FDA LinkGeneric 01/01/1989 - "These results indicate that high-dose diltiazem is well tolerated, safe, and effective in the prevention of early reinfarction and severe angina after non-Q-wave infarction." 08/14/1986 - "We conclude that diltiazem was effective in preventing early reinfarction and severe angina after non-Q-wave infarction and that it was also safe and generally well tolerated." 12/01/1999 - "In 2 earlier trials, diltiazem lessened cardiac events in patients with nonQ-wave infarctions and those without pulmonary congestion upon presentation. " 06/01/1995 - "Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research Group." 03/01/1994 - "Multicenter Diltiazem Post-Infarction Trial Research Group." Order ALL the reference details at left...
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/10/2000 - "RESULTS: We identified eight post-infarction studies for which subgroup analyses of diabetic subjects were available, four with beta blockers and four with ACE inhibitors. " 07/01/1994 - "Studies in animal models and conclusions from clinical trials have shown that angiotensin converting enzyme inhibitors also decrease late mortality and cardiac morbidity after infarction, likely through favorable effects on both hemodynamic and neurohumoral factors specific to this class of medication. " 12/01/1992 - "This provides a possible mechanism for the beneficial effect of ACE inhibitors in postmyocardial infarction trials. " 11/01/1992 - "The Survival and Ventricular Enlargement study (SAVE) has been the first to demonstrate the relationship between limitation of ventricular remodelling and improvement of the secondary prognosis of infarction obtained by angiotensin-converting enzyme inhibitors." 07/01/2006 - "Independent predictors of a favourable hospital course were as follows: admission to a hospital >600 beds (OR 0.64), reperfusion therapy (OR 0.63), early betablocker treatment (OR 0.46), and early application of ACE inhibitors (OR 0.48).CONCLUSION: Infarction patients over 75 have a very high hospital complication and mortality rate. " Order ALL the reference details at left...
9.	CalciumIBA 01/01/1992 - "Analysis of studies in acute infarction showed a neutral effect of calcium-antagonists with unchanged infarct-size, regional and global ventricular function or early mortality. " 08/01/1991 - "Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias." 09/01/2009 - "In non cardiac surgery statins, and calcium antagonists have minor beneficial effects while alpha(2) agonists could reduce perioperative mycoardial infarction and are included in the American College of Cardiology / American Heart Association Guidelines. " 05/01/2009 - "The extent of calcium deposits was positively correlated with infarction size and negatively with global left-ventricular function." 05/01/2009 - "The presence of calcium deposits was transient and associated with reperfused recent infarction. " Order ALL the reference details at left...
10.	Adenosine FDA LinkGeneric 06/20/2000 - "BACKGROUND: We have previously described a second window of protection against infarction in rabbits 24 to 72 hours after adenosine A(1) receptor (A(1)R) activation. " 05/01/2009 - "Recent trials such as INSPIRE (Adenosine Sestamibi Post-Infarction Evaluation) and the COURAGE (Results from Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-driven Drug Evaluation) Nuclear Imaging Substudy have established clearly that noninvasive risk stratification with vasodilator testing is an important and appropriate step in guiding medical therapy and invasive coronary intervention." 12/19/2006 - "METHODS: The INSPIRE (Adenosine Sestamibi Post-Infarction Evaluation) trial is a prospective multicenter trial which enrolled 728 clinically stable survivors of AMI who had gated ADSPECT within 10 days of hospital admission and subsequent 1-year follow-up. " 06/07/2005 - "BACKGROUND: Previous small studies suggest that adenosine may reduce the size of an evolving infarction. " 11/15/1999 - "METHODS: The AMISTAD trial was a prospective, open-label trial of thrombolysis with randomization to adenosine or placebo in 236 patients within 6 h of infarction onset. " Order ALL the reference details at left...

Therapies and Procedures

1.	Angioplasty (Angioplasties) 11/01/1999 - "Several studies (ACME, MASS, RITA 2) compared the efficacy of angioplasty with medical management in this context with concordant results: significant reduction in the frequency of angina and improved exercise capacity, without reduction in the number of serious events (death, infarction). " 07/01/1988 - "Rapid hemodynamic improvement in right ventricular infarction after coronary angioplasty." 05/01/1992 - "Angioplasty performed in the first three hours after the onset of symptoms is associated with an improvement in global an regional left ventricular function in patients with anterior infarction and altered initial left ventricular function. " 01/01/1997 - "These results were comparable to previously reported figures and confirm that primary angioplasty in acute infarction is possible and effective with an acceptable risk in a small urban community without on-site cardiac surgery." 12/24/1992 - "The degree of improvement in function was not influenced by the length of time between the infarction and the attempted angioplasty. " Order ALL the reference details at left...
2.	Thrombolytic Therapy 11/01/1997 - "Conservative intra-arterial thrombolytic therapy is considered to be the most effective treatment for renal infarction." 12/01/1986 - "In the long term, improved survival and enhanced quality of life are most evident after thrombolytic therapy in patients with larger anterior wall infarction, and less pronounced in patients with smaller inferior wall infarction." 07/01/2008 - "Compared with fibrinolytic therapy, primary percutaneous coronary intervention (PCI) results in improved short- and long-term survival, a lower incidence of recurrent infarction and a better left ventricular function. " 02/01/1994 - "This study indicates that postoperative intrathecal thrombolytic therapies, especially with less than 4 mg/d of tPA, are effective in lysing subarachnoid clot and preventing vasospasm and infarction safely." 03/18/1997 - "However, in these further identified AMI patients, 78% (7/9) had small enzyme rises with non-Q wave infarction and/or non-ST elevation and therefore may not have benefited from thrombolytic therapy in contrast to the Q wave/raised ST segment infarcts with large enzyme rises identified by clinical means. " Order ALL the reference details at left...
3.	Transplantation (Transplant Recipients) 03/01/2008 - "Transplantation of cultured MPCs into the ischemic border area significantly improved cardiac function by reducing infarction size. " 07/20/2007 - "The infarction volume and apoptotic activity of the transplanted hBMSCs were significantly decreased, and functional outcomes were significantly improved in the hBMSC transplantation and bFGF treatment group than in the control group. " 09/01/2009 - "The controlled release of MMP-1 improved cardiac functions of rats with chronic myocardiac infarction with or without transplantation of skeletal myoblasts. " 07/01/2004 - "Total body irradiation followed by transplantation with bone marrow from PKCdelta-null mice donors reduced infarct size and improved neurological outcome in WT mice, whereas marrow transplantation from WT donors increased infarction and worsened neurological scores in PKCdelta-null mice. " 08/01/2009 - "This study compared various aspects of the paracrine effect after transplantation of either bone marrow mononuclear cells (BMC) or skeletal myoblasts (SMB) into the post-infarction chronically failing heart. " Order ALL the reference details at left...
4.	Percutaneous Coronary Transluminal Angioplasty (PTCA) 06/01/1989 - "In conclusion, emergency CABG after failed percutaneous transluminal coronary angioplasty carries a significantly greater risk of operative death and perioperative infarction than elective CABG." 08/01/1989 - "Thus PTCA compared to medical therapy was associated with improved functional status and may decrease the risk of death and infarction in certain patient subsets. " 12/01/2003 - "The objective of this study was to assess the impact of both strategies on the indication for ICD in a consecutive series of post-infarction patients treated with primary PTCA. " 10/01/1996 - "50% of all PTCA were done during the diagnostic study (CA), direct PTCA for ongoing infarction in 2.8%. " 09/01/1996 - "48% of all PTCAs were done during the diagnostic study (CA), multivessel PTCA in 11%, direct PTCA for ongoing infarction in 2.3%. " Order ALL the reference details at left...
5.	Transplants (Transplant) 06/01/1995 - "Virtually all subgroup analyses, including age, nonanterior infarction location, patients undergoing bypass graft surgery and hypertensive patients, showed remarkable consistency with improved outcome with accelerated t-PA. " 04/01/1977 - "Factors responsible for improved survival include (1) reduced operative mortality, (2) fewer intraoperative infarctions, (3) more complete revascularization, and (4) higher patency rate of the internal mammary artery graft." 08/01/1975 - "Five patients with perioperative infarction but no patent grafts improved by only 1 NYHA class (mean), but ten patients with infarction and one or more grafts patent improved by 2.9 NYHA classes (mean). " 08/01/1975 - "Following coronary graft surgery in eight patients improved motion was found in association with graft patency in seven priviously delayed segments and two new areas of delayed wall motion associated with nonpatent grafts and electrocardiographic changes of infarction appeared. " 09/01/2004 - "Parallel in vivo studies showed that CP transplants improved behavioral performance and decreased the volume of infarction. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Infarction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 489 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>